MedTrace Logo

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

NCT07300683 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-12-24

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if anti-CCR9 CAR T cells (which will be made using the patient's own blood cells) are safe and which dose should be used in children and adults with T cell leukaemia and lymphoma.

Participants will:

* have T cells collected from their blood and these T cells will be used to make the CAR-T cells in a specialized laboratory.
* be admitted at the hospital a week before the CAR T cells infusion to receive a short course of chemotherapy drugs which prepare the body to receive the CAR T cells.
* be given the CAR T cells into their vein.
* stay in the hospital for a minimum of 2 weeks to be closely monitored
* following discharge, participants will come to the clinic for check-ups (approximately 12 visits in the first two years)
* during screening, treatment and follow up visits, participants will have physical examination, collection of blood samples and bone marrow biopsies and/or imaging tests (CT/PET-CT scans) depending on their type of T-cell cancer.

Conditions

  • T Cell Acute Lymphoblastic Leukemia
  • T Cell Lymphoblastic Lymphoma

Interventions

BIOLOGICAL

CARCCR9 T cells

Anti-CCR9 CAR T cells

Sponsors & Collaborators

  • Great Ormond Street Hospital Charity

    collaborator UNKNOWN

  • Medical Research Council

    collaborator OTHER_GOV

  • University College, London

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-11
Primary Completion
2027-12-31
Completion
2042-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07300683 on ClinicalTrials.gov